Print

BioCancell Therapeutics to Commence Enrollment of Phase IIb Pancreatic Cancer Clinical Trial  
10/6/2011 10:17:17 AM

TEL AVIV, Israel--(BUSINESS WIRE)--Tikcro Technologies Ltd. (Pink Sheets: TIKRF)(“Tikcro”) announced today that BioCancell, a clinical stage biotechnology company focused on developing targeted cancer therapies for solid cancer tumors, in which Tikcro holds approximately 26% on a fully diluted basis, has commenced enrollment of its Phase IIb pancreatic cancer clinical trial with a first treatment of the first patient.
//-->